Developer of a portable, point-of-care hemodynamic measurement system that uses proprietary sensor tech and machine learning to guide care.
Developer of a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System™ (CPS) is entirely non-invasive, trained to gold standard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 2, 2017 | Series B | $3.72M | 1 | Colle Capital Partners | — | Detail |
Mar 1, 2016 | Series A | $1.95M | 1 | Colle Capital Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Colle Capital Partners | Yes | Series B |